Securities claims related to Walmart’s disclosures about the scope of a Controlled Substances Act investigation by the Department of Justice have been dismissed.
A Delaware federal court ruled on April 8 that Walmart, which operates around 5,000 pharmacies, didn’t have an obligation to disclose an investigation into its pharmacy dispensing practices because the existence of an investigation on its own isn’t a liability that needs to be laid out for investors.
